The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM).
Sheeba K. Thomas
Consultant or Advisory Role - Celgene; Onyx (U); Pharmacyclics
Research Funding - Celgene; Immunomedics; Millennium; Novartis
A. Georgina Melendez
No relevant relationships to disclose
Lei Feng
No relevant relationships to disclose
Michael Wang
Research Funding - Celgene
Sattva Swarup Neelapu
Research Funding - Celgene
Jatin J. Shah
Consultant or Advisory Role - Array BioPharma; Celgene; Millennium; Novartis; Onyx
Research Funding - Array BioPharma; Celgene; Millennium; Novartis; Onyx
Robert Z. Orlowski
Consultant or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celgene; Millennium; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Onyx; Resverlogix
Donna M. Weber
No relevant relationships to disclose